Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis.

Details

Ressource 1Download: BIB_6265893B0A91.P001.pdf (351.17 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_6265893B0A91
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis.
Journal
Rheumatology International
Author(s)
Rizzoli Ren, Laroche Michel, Krieg Marc-Antoine, Frieling Isolde, Thomas Thierry, Delmas Pierre, Felsenberg Dieter
ISSN
1437-160X[electronic], 0172-8172[linking]
Publication state
Published
Issued date
2010
Volume
30
Number
10
Pages
1341-1348
Language
english
Abstract
The structural basis of the antifracture efficacy of strontium ranelate and alendronate is incompletely understood. We compared the effects of strontium ranelate and alendronate on distal tibia microstructure over 2 years using HR-pQCT. In this pre-planned, interim, intention-to-treat analysis at 12 months, 88 osteoporotic postmenopausal women (mean age 63.7 +/- 7.4) were randomized to strontium ranelate 2 g/day or alendronate 70 mg/week in a double-placebo design. Primary endpoints were changes in microstructure. Secondary endpoints included lumbar and hip areal bone mineral density (aBMD), and bone turnover markers. This trial is registered with http://www.controlled-trials.com, number ISRCTN82719233. Baseline characteristics of the two groups were similar. Treatment with strontium ranelate was associated with increases in mean cortical thickness (CTh, 5.3%), cortical area (4.9%) and trabecular density (2.1%) (all P < 0.001, except cortical area P = 0.013). No significant changes were observed with alendronate. Between-group differences in favor of strontium ranelate were observed for CTh, cortical area, BV/TV and trabecular density (P = 0.045, 0.041, 0.048 and 0.035, respectively). aBMD increased to a similar extent with strontium ranelate and alendronate at the spine (5.7% versus 5.1%, respectively) and total hip (3.3% versus 2.2%, respectively). No significant changes were observed in remodeling markers with strontium ranelate, while suppression was observed with alendronate. Within the methodological constraints of HR-pQCT through its possible sensitivity to X-ray attenuation of different minerals, strontium ranelate had greater effects than alendronate on distal tibia cortical thickness and trabecular volumetric density.
Keywords
quantitative computed-tomography, trabecular bone, postmenopausal osteoporosis, mineral density, mechanisms, strength, fractures, risk, microarchitecture, bisphosphonates
Pubmed
Web of science
Open Access
Yes
Create date
18/08/2010 11:33
Last modification date
20/08/2019 15:19
Usage data